Insulet Corporation (PODD)
Insulet Corporation (PODD) Presents At Baird Global Healthcare Conference 2025 Transcript
Insulet Corporation (NASDAQ:PODD ) Baird Global Healthcare Conference 2025 September 9, 2025 12:15 PM EDT Company Participants Eric Benjamin - Executive VP & COO Ana Chadwick - Executive VP & CFO Conference Call Participants Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Presentation Jeffrey Johnson Senior Research Analyst Jeff Johnson.
Insulet Corporation (PODD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Insulet Corporation (NASDAQ:PODD ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 3:00 PM EDT Company Participants Ashley McEvoy - CEO, President & Director Ana Chadwick - Executive VP & CFO Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Presentation Larry Biegelsen Senior Medical Device Equity Research Analyst All right. Welcome back.
Why Insulet (PODD) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Insulet Gains 77.2% in a Year: What's Driving the Rally?
PODD's 77.2% stock surge is fueled by Omnipod 5 expansion, global launches, strong Q2 profits and robust financial stability.
Insulet's Q2 Beat Is Impressive, But The Elevated Valuation Makes The Stock A Hold
PODD delivered strong Q2 results, exceeding revenue guidance, improving gross margin, and launching the Omnipod 5 iPhone app, strengthening its ecosystem position. Omnipod 5's pharmacy channel penetration and positive clinical data support sustained >20% annual revenue growth and margin expansion over the next 3-5 years. The market underestimates the long-term impact of pharmacy distribution, which reduces onboarding friction, broadens payer access, and improves retention economics.
Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise
PODD posts strong Q2 earnings and revenues and lifts its 2025 outlook, marking a decade of 20%+ constant-currency growth.
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Insulet Corporation (PODD) Q2 2025 Earnings Call Transcript
Insulet Corporation (NASDAQ:PODD ) Q2 2025 Earnings Call August 7, 2025 8:00 AM ET Company Participants Ana Maria Chadwick - Executive VP & CFO Ashley A. McEvoy - CEO, President & Director Eric Benjamin - Executive VP, Chief Product & Customer Experience Officer June Lazaroff - Senior Director of Investor Relations Conference Call Participants Danielle Joy Antalffy - UBS Investment Bank, Research Division David Harrison Roman - Goldman Sachs Group, Inc., Research Division Issie Kirby - Redburn (Europe) Limited, Research Division Jayson Tyler Bedford - Raymond James & Associates, Inc., Research Division Jeffrey D.
Insulet (PODD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Insulet (PODD) Surpasses Q2 Earnings and Revenue Estimates
Insulet (PODD) came out with quarterly earnings of $1.17 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $0.55 per share a year ago.
Curious about Insulet (PODD) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Insulet (PODD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
